The 2026 ASCO annual meeting featured an oral abstract kidney cancer session and a presentation by Dr. Toni Choueiri discussing a ctDNA analysis in participants with renal cell carcinoma (RCC) treated ...
Predictors of treatment duration in patients with mHSPC treated with ENZA: A post hoc analysis of ARCHES. Prior analyses from the phase 3 ARCHES trial demonstrated significant improvements in ...
Genomic and transcriptomic correlates of deep PSA response in patients with mHSPC. Despite major advances in combination treatment strategies for metastatic hormone-sensitive prostate cancer (mHSPC), ...
A randomized, double-blind, active-control, multicenter phase 3 trial of casdatifan and cabozantinib versus placebo and cabozantinib in patients with advanced clear cell RCC. Treatment options remain ...
As of the April 20, 2026, data cut-off, 82 patients had been treated, and 72 had completed primary response evaluation. Dr.
Lenherr SM. State-of-the-Art Lecture: New Developments in Urinary Catheters. Presented at: 2026 American Urological ...
Soputro delivered a podium presentation comparing outcomes between transvesical (TV) and extraperitoneal (EP) approaches for single-port robotic-assisted radical prostatectomy (SP-RARP). As ...
Annual Meeting featured a poster presentation by Dr. Akihiro Kumono and colleagues from Tokyo Women’s Medical University ...
The 25-year follow-up of the GÖTEBORG-1 trial 5 assessing active surveillance for screen-detected low and intermediate risk ...
At the morning plenary session on the final day of the 2026 American Urological Association Annual Meeting, Nima Nassiri presented the groundbreaking world’s first human bladder transplantation, ...
These differences remained significant beyond the initial 90 days, indicating durable diagnostic sensitivity and facilitating earlier, risk-appropriate treatment decisions, which supports broader ...
ImmunityBio to serve as sole U.S. Biologics License Application applicant for the Tokyo strain of BCG and plans to engage with U.S. Food and Drug Administration (FDA) on regulatory pathway to address ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results